Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem ; 56: 116599, 2022 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-35041998

RESUMEN

The aminobenzamide is selective to class I histone deacetylases (HDACs) and displays unique tight-binding/slow-off HDAC-binding mechanism. Herein, we report a series of 9-substituted purine aminobenzamides that selectively inhibit class I HDACs. The activities in vitro showed compound 9d exhibited 12 folds more potent than MS-275 against HDAC1 isoform and showed excellent inhibitory activity on cancer cells, including HCT-116, MDA-MB-231, K562 cell lines. The metabolic stability of 9d was much better than that of the well-known HDAC inhibitor SAHA. Pulse exposure test of western blot assay demonstrated that 9a, 9d induced histone acetylation in a similar manner to MS-275. Further biological validation demonstrated that 9d prevented cell transition from G1 phase to S phase by reducing Cyclin D1, CDK2 and lifting p21, induced early apoptosis by upregulating BAX and downregulating Bcl-2 in HCT-116 cells.


Asunto(s)
Antineoplásicos/farmacología , Benzamidas/farmacología , Inhibidores de Histona Desacetilasas/farmacología , Histona Desacetilasas/metabolismo , Purinas/farmacología , Antineoplásicos/síntesis química , Antineoplásicos/química , Benzamidas/síntesis química , Benzamidas/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Inhibidores de Histona Desacetilasas/síntesis química , Inhibidores de Histona Desacetilasas/química , Humanos , Simulación del Acoplamiento Molecular , Estructura Molecular , Purinas/química , Relación Estructura-Actividad
2.
Chem Pharm Bull (Tokyo) ; 66(12): 1199-1202, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30504634

RESUMEN

Four new prenylated 2-arylbenzofurans, namely artopithecins A-D (1-4), together with five known compounds (5-9) were isolated from the twigs of Artocarpus pithecogallus for the first time. Their structures were elucidated based on extensive spectroscopic analysis and in comparison with literature data. All isolates were evaluated for their inhibitory activities against mushroom tyrosinase. Compounds 3 and 4 displayed significant tyrosinase inhibitory activities with IC50 values of 37.09±0.33 and 38.14±0.21 µM, respectively.


Asunto(s)
Artocarpus/química , Benzofuranos/farmacología , Inhibidores Enzimáticos/farmacología , Monofenol Monooxigenasa/antagonistas & inhibidores , Tallos de la Planta/química , Agaricales/enzimología , Benzofuranos/química , Benzofuranos/aislamiento & purificación , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/aislamiento & purificación , Estructura Molecular , Monofenol Monooxigenasa/metabolismo , Prenilación , Relación Estructura-Actividad
3.
Chem Pharm Bull (Tokyo) ; 66(4): 434-438, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29607909

RESUMEN

Two new prenylated flavones, artocarnin A (2) and carpachromenol (12), together with 13 known prenylflavonoids (1, 3-11, 13-15) were isolated from the twigs of Artocarpus nigrifolius for the first time. Their structures were elucidated by high resolution-electrospray ionization (HR-ESI)-MS, NMR spectroscopic analysis, and in comparison with the reported data. Compounds 1-15 were evaluated for their antiproliferative effects against SiHa and SGC-7901 human cancer cell lines in vitro. The most active compound, eleocharin A (10), showed significant cytotoxicity on SiHa cells (IC50=0.7±0.1 µM) and inhibitory activity against SGC-7901 cells (IC50=8.3±0.2 µM) and could be considered as potential lead compound for further development of novel anti-tumor agents.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Artocarpus/química , Flavonoides/farmacología , Corteza de la Planta/química , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Flavonoides/química , Flavonoides/aislamiento & purificación , Humanos , Estructura Molecular , Relación Estructura-Actividad , Células Tumorales Cultivadas
4.
Pediatr Hematol Oncol ; 32(1): 18-25, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24852330

RESUMEN

PURPOSE: This study was to determine the efficacy of vincristine and irinotecan in children with relapsed hepatoblastoma (HB). METHODS: A total of 10 patients with relapsed HB were enrolled. Three patients were excluded. Patients received irinotecan 50 mg/m(2)/day, day 1-5 and vincristine 1.5 mg/m(2)/day, day 1, repeated every 3 weeks. The maximum cycles were eight. Reevaluation of tumor was performed every two cycles. The primary outcome was the rate of complete resection. Secondary outcomes were event-free survival (EFS) and overall survival (OS). RESULTS: Of the seven patients assessable for response, one patient with normal AFP level showed a progressive disease and withdrew. He finally died 6 months later. Four had PR, all of them underwent a second surgery and achieved complete resection. Two patients had SD, one patient relapsed 6 months after orthotopic liver transplantation and died, the other one undergoing surgery had micro margin positive, he relapsed again but alive. The rate of complete resection was 71.4% (including orthotopic liver transplantation). The 2-year EFS and OS for the whole group were 57.1% (95% CI, 12.7% to 34.2%) and 71.4% (95% CI, 16.39% to 37.4%), respectively. CONCLUSIONS: The combination of irinotecan and vincristine has a significant antitumor activity and acceptable toxicity in children with relapsed HB.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Hepatoblastoma , Neoplasias Hepáticas , Recurrencia Local de Neoplasia , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Preescolar , Supervivencia sin Enfermedad , Hepatoblastoma/mortalidad , Hepatoblastoma/terapia , Humanos , Lactante , Irinotecán , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/terapia , Trasplante de Hígado , Recurrencia Local de Neoplasia/mortalidad , Recurrencia Local de Neoplasia/terapia , Tasa de Supervivencia , Factores de Tiempo , Vincristina/administración & dosificación
5.
Zhong Yao Cai ; 38(3): 601-5, 2015 Mar.
Artículo en Zh | MEDLINE | ID: mdl-26495663

RESUMEN

OBJECTIVE: To establish analysis methods for fingerprint of Kanggongyan series by HPLC. METHODS: A Shiseido CAP-CELL PAK C18(250 mm x 4. 6 mm, 3 µm) column was used with acetonitrile-0. 5% phosphoric acid as the mobile phase by gradient elution. The flow rate was 0. 8 mL/min, the column temperature was 30 °C, and the detection wavelength was set at 280 nm during 0 ~ 44 min and at 332 nm during 44 ~ 115 min. RESULTS: Ten common peaks were selected as characteristic peaks in the chromatogram of Kanggongyan particles, eleven common peaks were selected as characteristic peaks in the chromatogram of Kanggongyan tablets and capsules ,the similarities were greater than 0. 9 among all batches. CONCLUSION: The method is simple, steady and repeatable. It provides a basis for the quality control of Kanggongyan series.


Asunto(s)
Cromatografía Líquida de Alta Presión , Medicamentos Herbarios Chinos/química , Cápsulas , Control de Calidad , Comprimidos
6.
J Pediatr Hematol Oncol ; 36(4): 271-5, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24309602

RESUMEN

PURPOSE: The use of neoadjuvant chemotherapy has improved the survival of patients with hepatoblastoma (HB). However, an increased number of treatment complications and toxic deaths, particularly from heart failure, have been observed with doxorubicin treatment. We have applied cisplatin as a single agent to treat children with high-risk HB to improve event-free survival (EFS). METHODS: Between 2007 and 2009, 14 patients with untreated high-risk HB were enrolled in this study. All the patients received a single-agent treatment of cisplatin. The initial cisplatin cycle was administered in a continuous intravenous 24-hour infusion of 80 mg/m/24 h. The primary outcome was the rate of complete resection. Secondary outcomes were EFS and overall survival (OS). RESULTS: Eleven patients (78.6%) had an overall partial response. Two patients (14.3%) had stable disease. One patient experienced (7.1%) progression. Of the 4 patients who presented with lung metastases initially, 1 patient achieved complete response, 2 patients achieved partial response, and 1 patient experienced progression during preoperative chemotherapy. The complete resection rate was 78.6% (95% CI, 49%-95%). The Kaplan-Meier estimates of 2-year EFS and OS for the whole group were 64.3% (95% CI, 35%-87%) and 85.7% (95% CI, 57%-98%), respectively. The 2-year EFS and OS rates of patients who achieved complete resection were 81.8% (95% CI, 48%-98%) and 100% (95% CI, 62%-100%), respectively. CONCLUSIONS: The single-agent cisplatin had less toxicity than cisplatin plus doxorubicin and achieved an equal rate of complete resection in high-risk HB compared with conventional multiagent chemotherapy.


Asunto(s)
Antineoplásicos/administración & dosificación , Cisplatino/administración & dosificación , Hepatoblastoma/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Adolescente , Antineoplásicos/efectos adversos , Niño , Preescolar , Cisplatino/efectos adversos , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Hepatoblastoma/mortalidad , Hepatoblastoma/patología , Humanos , Lactante , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/patología , Masculino , Estudios Retrospectivos , Tasa de Supervivencia
7.
Chem Pharm Bull (Tokyo) ; 62(9): 898-905, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25177019

RESUMEN

A series of novel benzyloxyurea derivatives was designed, synthesized by substituting different benzyls or phenyls on N,N'-positions of the hydroxyurea (HU). These target compounds were evaluated for their anticancer activity in vitro against human leukemia cell line K562 and murine leukemia cell line L1210 in comparison with HU by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Some of the compounds showed promising anticancer activity against the cells. Molecular docking experiments with Saccharomyces cerevisiae R1 domain indicated that 4a and 4f' have stronger affinity than 4m and 4n. Flow cytometry study showed that compound 4g exerted greater apoptotic activity against K562 cells line than HU.


Asunto(s)
Antineoplásicos/farmacología , Urea/análogos & derivados , Urea/farmacología , Animales , Antineoplásicos/síntesis química , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Células K562 , Leucemia L1210/patología , Ratones , Simulación del Acoplamiento Molecular , Espectroscopía de Protones por Resonancia Magnética , Espectroscopía Infrarroja por Transformada de Fourier , Urea/síntesis química
8.
Bioorg Med Chem Lett ; 23(9): 2491-4, 2013 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-23548547

RESUMEN

Two new prenylated para-xylenes, named caulerprenylols A (1) and B (2), were isolated from the green alga Caulerpa racemosa, collected from the Zhanjiang coastline, China. The structures of the two metabolites were elucidated on the basis of detailed spectroscopic analysis. This is the first report of prenylated para-xylenes from marine algae and from marine organisms as well. Moreover, caulerprenylol B (2) is also characterized by an uncommon indane ring system. In in vitro bioassays, the new compounds exhibited a broad spectrum of antifungal activity against Candida glabrata (537), Trichophyton rubrum (Cmccftla), and Cryptococcus neoformans (32609) with MIC80 values between 4 and 64 µg/mL when compared to amphotericin B (MIC80 values of 2.0, 1.0, and 4.0 µg/mL, respectively) as a positive control and showed no growth inhibition activity against the tumor cells HL60 and A549.


Asunto(s)
Antifúngicos/química , Caulerpa/química , Xilenos/química , Antifúngicos/aislamiento & purificación , Antifúngicos/farmacología , Candida glabrata/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cryptococcus neoformans/efectos de los fármacos , Células HL-60 , Humanos , Espectroscopía de Resonancia Magnética , Conformación Molecular , Trichophyton/efectos de los fármacos , Xilenos/aislamiento & purificación , Xilenos/farmacología
11.
Zhonghua Fu Chan Ke Za Zhi ; 42(1): 6-8, 2007 Jan.
Artículo en Zh | MEDLINE | ID: mdl-17331412

RESUMEN

OBJECTIVE: To explore the clinical efficacy of focused ultrasound for patients with white lesions of the vulva, as well as its safety and feasibility. METHODS: Clinical data of 941 patients with white lesions of the vulva treated with focused ultrasound from June 2003 to December 2005 were retrospectively reviewed. The mean age of the patients was 40.8 years (18 - 70 years) and the median course of the disease was 6.2 years (3 months - 45 years). Meanwhile, pathological diagnosis was performed in all the patients before treatment, in which 498 cases were squamous hyperplasia, 342 cases were lichen sclerosus and 101 cases were lichen sclerosus with squamous hyperplasia. Patients were followed up and therapeutic effects of focused ultrasound was evaluated at 6 and 12 months after the treatment, respectively. The symptoms of pruritus in the vulva and the changes in the color and elasticity of the vulvar lesions were observed. RESULTS: Of all the patients, 900 were followed up after the treatment, and the ratio of effectiveness was 94.9%. Only 46 patients (5.1%) had no response to the therapy. Of the effective patients, 434 cases were completely cured (48.2%), and 420 cases were improved (46.7%). Pruritus of vulva recurred in 101 patients (11.2%) one year after treatment; however, these patients still had a response to the second or third treatment. CONCLUSIONS: Focused ultrasound therapy is a highly effective instrument in treatment of white lesions of the vulva. It can not only relieve the symptoms of itching, but is also helpful in recovering the color and elasticity of the vulva.


Asunto(s)
Terapia por Ultrasonido/métodos , Enfermedades de la Vulva/terapia , Liquen Escleroso Vulvar/terapia , Adolescente , Adulto , Anciano , Edema/etiología , Edema/terapia , Femenino , Humanos , Hiperplasia , Persona de Mediana Edad , Estudios Retrospectivos , Enfermedades de la Piel/etiología , Enfermedades de la Piel/terapia , Resultado del Tratamiento , Vulva/patología , Enfermedades de la Vulva/patología , Liquen Escleroso Vulvar/patología
12.
Iran J Pediatr ; 25(1): e266, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26199695

RESUMEN

BACKGROUND: Clinical presentations of paraneoplastic syndromes in neuroblastoma may multiply. Review of the clinical data and the literature on this syndrome may help in the diagnosis of neuroblastoma. OBJECTIVES: In order to make more accurate diagnosis, we reviewed the clinical data and the literature on this syndrome. PATIENTS AND METHODS: Between April 2007 and April 2012, 68 children were diagnosed with neuroblastoma or ganglioneuroblastoma in our institution, 9 of which presented exclusively with paraneoplastic syndromes and were not treated with chemotherapy prior to diagnosis. After the diagnosis, all patients received chemotherapy and operation on NB97 protocol. RESULTS: Among 68 pediatric patients with neuroblastoma or ganglioneuroblastoma, 4 (5.9%) patients suffered from neurological complications at diagnosis, 2 (2.9%) patients had digestive tract disorders, 2 (2.9%) patients had immune diseases, and 1 (1.5%) suffered from hematological disorder (without bone marrow involvement). All paraneoplastic syndrome patients achieved complete remission on paraneoplastic syndrome before completion of chemotherapy. CONCLUSIONS: Neuroblastoma may present with a range of non-specific neurologic symptoms in addition to the well-known opsoclonus-myoclonus syndrome and cerebellar ataxia. In any case, the presence of unexplained neurologic manifestations and other common clinical presentations such as rash, constipation, diarrhea, and especially immune disorders in an otherwise healthy child had raised the possibility of paraneoplastic syndrome due to the presence of an undiagnosed tumor.

13.
Phytochemistry ; 103: 162-170, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24731260

RESUMEN

A ring-cleaved sesquiterpene, named seco-laurokamurone, four laurane-type sesquiterpenes, laurepoxyene, 3ß-hydroperoxyaplysin, 3α-hydroperoxy-3-epiaplysin, and 8,10-dibromoisoaplysin, one laurokamurane-type sesquiterpene, laurokamurene D, and one bisabolane-type sesquiterpene, (5S)-5-acetoxy-ß-bisabolene, have been isolated from a re-collection of the red alga Laurencia okamurai Yamada, together with six other known sesquiterpenes. Their structures, including relative configuration, were elucidated by detailed analysis of spectroscopic data, and by comparison with data for related known compounds. In addition, on the basis of chemical conversions, degradation results, and biogenetic considerations, the absolute configurations of several of these compounds were also tentatively proposed. seco-Laurokamurone possesses an unprecedented carbon skeleton, formed from an oxidative cleavage of the laurokamurane skeleton, and laurokamurene D represents the fourth example of a laurokamurane-type sesquiterpene from a natural source. The in vitro antifungal activity of many of these compounds was evaluated against four fungi (Cryptococcus neoformans, Candida glabrata, Trichophyton rubrum, and Aspergillus fumigatus), as well as assessing cytotoxicity against HL-60 and A-549 human cancer cell lines. The compounds studied displayed moderate activities, relative to controls.


Asunto(s)
Antifúngicos/química , Laurencia/química , Sesquiterpenos/química , Antifúngicos/efectos adversos , Antifúngicos/farmacología , Aspergillus fumigatus/efectos de los fármacos , Candida glabrata/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Cryptococcus neoformans/efectos de los fármacos , Humanos , Estructura Molecular , Sesquiterpenos/efectos adversos , Sesquiterpenos/farmacología , Trichophyton/efectos de los fármacos
14.
Int J Gynaecol Obstet ; 120(2): 124-6, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23245674

RESUMEN

OBJECTIVE: To determine the prevalence and genotype distribution of human papillomavirus (HPV) infection among Chinese patients with mucopurulent cervicitis (MPC) or cervical cancer (CC). METHODS: In total, 191 cases of CC (n=66), acute MPC (n=84), and healthy cervix controls (n=41) were initially included; samples were collected between May 21, 2008, and October 9, 2011. Cervical specimens were screened for HPV using a nested polymerase chain reaction assay and DNA sequencing. RESULTS: Overall prevalence of HPV infection was 20.0% in the control group, 53.3% in the MPC group, and 93.8% in the CC group. The predominant genotype detected in all 3 groups was the oncogenic variant HPV 16 (87.7%, 18.7%, and 10.0% in the CC, MPC and control specimens, respectively). The second most frequent genotype among patients with MPC was HPV 58. This variant is also oncogenic and was detected at a higher rate in the MPC group (9.3%) than in the control (2.5%) and CC (1.5%) groups. CONCLUSION: Infection with HPV was prevalent among Chinese women with MPC or CC. Furthermore, the high prevalence of oncogenic genotypes observed among HPV-positive patients with MPC suggests that this group is at increased risk of developing CC.


Asunto(s)
Papillomavirus Humano 16/aislamiento & purificación , Infecciones por Papillomavirus/virología , Neoplasias del Cuello Uterino/virología , Cervicitis Uterina/virología , Adulto , Estudios de Casos y Controles , China/epidemiología , Femenino , Genotipo , Papillomavirus Humano 16/genética , Humanos , Persona de Mediana Edad , Infecciones por Papillomavirus/epidemiología , Prevalencia , Adulto Joven
15.
Fitoterapia ; 91: 15-20, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23978579

RESUMEN

Racemosin A (1), a structurally unique bisindole alkaloid possessing the seco-indolo[3,2-a]carbazole skeleton with two uncommon indolinenone units both conjugated with a methyl propenoate moiety, and its unusual cyclized derivative, racemosin B (2), were isolated from the green alga Caulerpa racemosa, together with the most commonly encountered pigment in the genus Caulerpa, caulerpin (3). Their structures were elucidated by extensive spectroscopic analysis and by comparison with data for related known compounds. A plausible biosynthetic pathway of 1 and 2 was proposed. In a neuro-protective assay, compound 1 significantly attenuated the Aß2(5-35)-induced SH-SY5Y cell damage with a 14.6% increase in cell viability at the concentration of 10µM when compared to epigallocatechin gallate (EGCG, 16.57% increase at 10 µM) as the positive control.


Asunto(s)
Caulerpa/química , Alcaloides Indólicos/aislamiento & purificación , Fármacos Neuroprotectores/aislamiento & purificación , Extractos Vegetales/química , Supervivencia Celular/efectos de los fármacos , Humanos , Alcaloides Indólicos/química , Alcaloides Indólicos/farmacología , Indoles/química , Indoles/aislamiento & purificación , Estructura Molecular , Neuroblastoma , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/farmacología , Extractos Vegetales/farmacología
16.
Chin Med J (Engl) ; 123(15): 2051-7, 2010 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-20819541

RESUMEN

BACKGROUND: Bacterial vaginosis (BV) is one of the most common infectious diseases among sexually active women and is associated with the increased acquisition of a variety of sexually transmitted diseases. This study aimed to compare the efficacy of a non-antibiotic sucrose gel against an antibiotic metronidazole gel for the treatment of BV. METHODS: A randomized, double-blinded, multi-center, parallel-group, placebo-controlled phase III clinical trial was conducted at eight hospitals in China. A total of 560 subjects with clinically diagnosed BV were randomly assigned into three groups for vaginally receiving sucrose, metronidazole, and placebo gels, respectively, twice daily for five consecutive days. The efficacy of therapeutic cure, defined as an achievement of both microbiologic cure (a Nugent score of 3 or less) and clinical cure (a resolution of the clinical findings from the baseline visit), was evaluated at the 1st and 2nd test-of-cure (TOC) visits at 7-10 and 21-35 days after the start of treatment, respectively. RESULTS: Therapeutic cure rates for sucrose, metronidazole, and placebo gel groups were 83.13%, 71.30% and 0.92%, at the 1st TOC, and 61.04%, 66.67% and 7.34%, at the 2nd TOC, respectively. While there was no significant difference between the sucrose and metronidazole gel groups at the 2nd TOC (P = 0.305), and sucrose gel was more effective than metronidazole gel at the 1st TOC (P = 0.009). CONCLUSION: These findings suggest that sucrose gel restores normal vaginal flora more rapidly than metronidazole gel and can be used as a novel treatment for BV.


Asunto(s)
Antibacterianos/uso terapéutico , Sacarosa/uso terapéutico , Vaginosis Bacteriana/tratamiento farmacológico , Administración Intravaginal , Adolescente , Adulto , Antibacterianos/administración & dosificación , Método Doble Ciego , Femenino , Humanos , Metronidazol/administración & dosificación , Metronidazol/uso terapéutico , Persona de Mediana Edad , Sacarosa/administración & dosificación , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA